List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6682780/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Latent human herpesvirus 6 infection of human monocytes/macrophages. Journal of General Virology, 1991, 72, 1401-1408.	1.3	333
2	Serum Neutrophil Extracellular Trap Levels Predict Thrombotic Microangiopathy after Allogeneic Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1683-1689.	2.0	97
3	Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 1563-1570.	1.3	83
4	Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1749-1758.	2.0	80
5	Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with an Historical Control Group. Biology of Blood and Marrow Transplantation, 2018, 24, 1264-1273.	2.0	57
6	Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplantation, 2016, 51, 205-211.	1.3	52
7	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood, 2015, 126, 415-422.	0.6	49
8	Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1441-1449.	2.0	49
9	Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leukemia and Lymphoma, 2017, 58, 1840-1848.	0.6	40
10	Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation. International Journal of Hematology, 2018, 108, 66-75.	0.7	39
11	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone Marrow Transplantation, 2019, 54, 1789-1798.	1.3	39
12	Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. Blood Advances, 2019, 3, 3626-3634.	2.5	39
13	Human herpesvirusâ€6 encephalitis during hematopoietic stem cell transplantation leads to poor prognosis. Transplant Infectious Disease, 2013, 15, 195-201.	0.7	31
14	Enhancement of neutrophil autophagy by an IVIG preparation against multidrug-resistant bacteria as well as drug-sensitive strains. Journal of Leukocyte Biology, 2015, 98, 107-117.	1.5	28
15	Impact of the Use and Type of Antibiotics on Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 2178-2183.	2.0	28
16	Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy. Journal of Hematology and Oncology, 2015, 8, 102.	6.9	27
17	Sensitive and validated LCâ€MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients. Biomedical Chromatography, 2015, 29, 1309-1316.	0.8	27
18	Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplantation, 2021, 56, 1126-1133.	1.3	27

#	Article	IF	CITATIONS
19	Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. Haematologica, 2016, 101, 644-652.	1.7	26
20	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1515-1522.	2.0	24
21	Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute. Biology of Blood and Marrow Transplantation, 2017, 23, 2159-2165.	2.0	23
22	Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life. Biology of Blood and Marrow Transplantation, 2019, 25, 1851-1858.	2.0	23
23	Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation. Supportive Care in Cancer, 2020, 28, 3189-3196.	1.0	23
24	Improved prognosis with additional mediumâ€dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. American Journal of Hematology, 2018, 93, 47-57.	2.0	23
25	Successful treatment with intravesical cidofovir for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A case report and a review of the literature. Journal of Infection and Chemotherapy, 2016, 22, 495-500.	0.8	22
26	Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2016, 51, 96-102.	1.3	22
27	Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transplantation, 2014, 49, 859-861.	1.3	21
28	Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 717-725.	2.0	21
29	Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis. Haematologica, 2018, 103, 163-171.	1.7	21
30	Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey. Bone Marrow Transplantation, 2019, 54, 611-615.	1.3	21
31	Allogeneic haematopoietic cell transplantation with reducedâ€intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. British Journal of Haematology, 2015, 168, 463-466.	1.2	20
32	Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan. Biology of Blood and Marrow Transplantation, 2018, 24, 1180-1186.	2.0	19
33	High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Biology of Blood and Marrow Transplantation, 2019, 25, 899-905.	2.0	18
34	Vesnarinone Causes Oxidative Damage by Inhibiting Catalase Function through Ceramide Action in Myeloid Cell Apoptosis. Molecular Pharmacology, 2002, 61, 620-627.	1.0	17
35	Intravenous immunoglobulin enhances the killing activity and autophagy of neutrophils isolated from immunocompromised patients against multidrug-resistant bacteria. Biochemical and Biophysical Research Communications, 2015, 464, 94-99.	1.0	17
36	The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. Hematological Oncology, 2019, 37, 54-61.	0.8	16

#	Article	IF	CITATIONS
37	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia, 2022, 36, 1132-1138.	3.3	16
38	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. Blood Cancer Journal, 2022, 12, .	2.8	16
39	Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. Bone Marrow Transplantation, 2019, 54, 393-401.	1.3	15
40	Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Advances, 2020, 4, 3169-3179.	2.5	15
41	Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 474-479.	2.0	14
42	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. Clinical Cancer Research, 2021, 27, 4825-4835.	3.2	14
43	Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. International Journal of Hematology, 2011, 93, 532-541.	0.7	13
44	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. International Journal of Hematology, 2017, 105, 59-69.	0.7	13
45	Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. Bone Marrow Transplantation, 2019, 54, 326-329.	1.3	13
46	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60–69Âyears with myelodysplastic syndrome. Annals of Hematology, 2019, 98, 1367-1381.	0.8	13
47	Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission. Biology of Blood and Marrow Transplantation, 2020, 26, 463-471.	2.0	13
48	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 387-394.	1.3	13
49	High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation. Cancer Medicine, 2017, 6, 120-128.	1.3	12
50	Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning. Blood Advances, 2022, 6, 2618-2627.	2.5	12
51	Increased nonâ€relapse mortality due to highâ€dose cytarabine plus <scp>CY</scp> / <scp>TBI</scp> in <scp>BMT</scp> / <scp>PBSCT</scp> for acute lymphoblastic leukaemia in adults. British Journal of Haematology, 2017, 178, 106-111.	1.2	11
52	Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group. Annals of Hematology, 2019, 98, 2815-2823.	0.8	11
53	Higher exercise tolerance early after allogeneic hematopoietic stem cell transplantation is the predictive marker for higher probability of later social reintegration. Scientific Reports, 2021, 11, 7190.	1.6	11
54	Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation. Bone Marrow Transplantation, 2015, 50, 312-314.	1.3	10

#	Article	IF	CITATIONS
55	A Rare Case of Adult Autoimmune Neutropenia Successfully Treated with Prednisolone. Internal Medicine, 2017, 56, 1415-1419.	0.3	10
56	Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis. Diagnostic Microbiology and Infectious Disease, 2018, 90, 123-131.	0.8	10
57	Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis. Platelets, 2019, 30, 946-956.	1.1	10
58	Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. Biology of Blood and Marrow Transplantation, 2020, 26, 1543-1551.	2.0	10
59	Possible nosocomial transmission of virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2021, 100, 753-761.	0.8	10
60	Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease. International Journal of Hematology, 2011, 93, 673-676.	0.7	9
61	High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study. Bone Marrow Transplantation, 2016, 51, 1636-1639.	1.3	9
62	Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. Biology of Blood and Marrow Transplantation, 2018, 24, 1441-1448.	2.0	9
63	Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2085-2095.	0.6	9
64	Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplantation, 2021, 56, 2779-2787.	1.3	9
65	Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. International Journal of Hematology, 2009, 89, 538-545.	0.7	8
66	Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. International Journal of Hematology, 2016, 103, 423-428.	0.7	8
67	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Annals of Hematology, 2018, 97, 2173-2183.	0.8	8
68	Successful granulocyte apheresis using medium molecular weight hydroxyethyl starch. International Journal of Hematology, 2019, 110, 729-735.	0.7	8
69	Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia. Annals of Hematology, 2019, 98, 2179-2186.	0.8	8
70	Drug monitoring for mycophenolic acid in graft―vs â€host disease prophylaxis in cord blood transplantation. British Journal of Clinical Pharmacology, 2020, 86, 2464-2472.	1.1	8
71	Expanded indications for lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1549-1557.e4.	0.4	8
72	A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 365.e1-365.e7.	0.6	8

#	Article	IF	CITATIONS
73	Lymphocyte Area Under the Curve as a Predictive Factor for Viral Infection after Allogenic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 587-593.	2.0	7
74	Favorable Outcomes after Single Cord Blood Transplantation for Patients with High-Risk Hematologic Diseases: A Single-Institute Retrospective Analysis. Transplantation and Cellular Therapy, 2021, 27, 495.e1-495.e9.	0.6	7
75	Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone Marrow Transplantation, 2021, 56, 2302-2304.	1.3	7
76	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. Annals of Hematology, 2017, 96, 469-478.	0.8	6
77	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. Biology of Blood and Marrow Transplantation, 2017, 23, 75-80.	2.0	6
78	Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. Scientific Reports, 2020, 10, 21418.	1.6	6
79	Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. Transplantation and Cellular Therapy, 2021, 27, 314.e1-314.e10.	0.6	6
80	Prediction of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm. Blood, 2018, 132, 68-68.	0.6	6
81	The First-in-Human Clinical Trial of iPSC-Derived Platelets (iPLAT1): Autologous Transfusion to an Aplastic Anemia Patient with Alloimmune Platelet Transfusion Refractoriness. Blood, 2021, 138, 351-351.	0.6	6
82	A case of neurolymphomatosis caused by follicular lymphoma successfully treated with bendamustine. Clinical Case Reports (discontinued), 2016, 4, 23-25.	0.2	5
83	Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab. Annals of Hematology, 2020, 99, 887-889.	0.8	5
84	Physical function after lung transplantation for late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Supportive Care in Cancer, 2021, 29, 5447-5454.	1.0	5
85	Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up. Journal of Cancer Survivorship, 2022, 16, 1004-1015.	1.5	5
86	Outcome of therapyâ€related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Hematological Oncology, 2022, 40, 752-762.	0.8	5
87	Efficacy of Dexamethasone for Acute Primary Immune Thrombocytopenia Compared to Prednisolone: A Systematic Review and Meta-analysis. TH Open, 2017, 01, e73-e81.	0.7	4
88	Outcome of allogeneic hematopoietic stem cell transplantation in cases of mature T/NK-cell neoplasms: a single-center retrospective analysis. Annals of Hematology, 2017, 96, 323-326.	0.8	4
89	Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan. Biology of Blood and Marrow Transplantation, 2019, 25, e23-e27.	2.0	4
90	NK-cell post-transplant lymphoproliferative disease with chronic active Epstein–Barr virus infection-like clinical findings. International Journal of Infectious Diseases, 2019, 88, 31-33.	1.5	4

#	Article	IF	CITATIONS
91	Neutropenia and renal dysfunction due to intravesical cidofovir for virusâ€associated hemorrhagic cystitis after kidney and allogenic hematopoietic stem cell transplantations. Transplant Infectious Disease, 2019, 21, e13185.	0.7	4
92	Impact of cumulative steroid dose on infectious diseases after allogenic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2019, 21, e13049.	0.7	4
93	Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group. Biology of Blood and Marrow Transplantation, 2020, 26, 2346-2358.	2.0	4
94	Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. Bone Marrow Transplantation, 2020, 55, 1955-1965.	1.3	4
95	Analysis of factors associated with patient-reported physical functioning scores at discharge of allogeneic hematopoietic stem cell transplantation patients: a cross-sectional study. Supportive Care in Cancer, 2021, 29, 7569-7576.	1.0	4
96	Nextâ€generation sequencing in two cases of <i>de novo</i> acute basophilic leukaemia. Journal of Cellular and Molecular Medicine, 2021, 25, 7095-7099.	1.6	4
97	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. Bone Marrow Transplantation, 2021, 56, 2964-2974.	1.3	4
98	Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. BMJ Open, 2020, 10, e040467.	0.8	4
99	Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. Transplantation, 2022, 106, 1279-1287.	0.5	4
100	18F-FDG PET/CT and MRI findings in a case of granulocytic sarcoma of the breast. International Journal of Hematology, 2016, 103, 117-118.	0.7	3
101	Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. International Journal of Hematology, 2020, 112, 609-613.	0.7	3
102	Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab. Hematological Oncology, 2020, 38, 146-152.	0.8	3
103	Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatric Blood and Cancer, 2020, 67, e28181.	0.8	3
104	A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab. Annals of Hematology, 2020, 99, 2699-2701.	0.8	3
105	Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. Bone Marrow Transplantation, 2021, 56, 2410-2422.	1.3	3
106	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapyâ€refractory or relapsed disease prior to allogeneic stem cell transplantation. British Journal of Haematology, 2021, 194, 403-413.	1.2	3
107	Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders. Annals of Hematology, 2020, 99, 1565-1573.	0.8	3
108	Evaluation of indices for predicting recovery of exercise tolerance in patients surviving allogenic hematopoietic stem cell transplantation. Supportive Care in Cancer, 2022, 30, 4027-4034.	1.0	3

#	Article	IF	CITATIONS
109	Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. Cytotherapy, 2022, 24, 1013-1025.	0.3	3
110	Adult patients with Ph+ ALL benefit from conditioning regimen of mediumâ€dose VP16 plus CY/TBI. Hematological Oncology, 2022, 40, 1041-1055.	0.8	3
111	Chronic myeloid leukemia following treatment for bilateral retinoblastoma. Pediatric Blood and Cancer, 2018, 65, e27107.	0.8	2
112	Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study. BMC Infectious Diseases, 2019, 19, 38.	1.3	2
113	Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases. Bone Marrow Transplantation, 2019, 54, 1710-1712.	1.3	2
114	Impact of HLA class I allele-level mismatch on viral infection within 100Âdays after cord blood transplantation. Scientific Reports, 2020, 10, 21150.	1.6	2
115	Report of a â€~consensus' on the lines of therapy for primary immune thrombocytopenia in adults, promoted by the Italian Gruppo di Studio delle Piastrine. Platelets, 2020, 31, 461-473.	1.1	2
116	Personalized prediction of overall survival in patients with AML in nonâ€complete remission undergoing alloâ€HCT. Cancer Medicine, 2021, 10, 4250-4268.	1.3	2
117	Impact of HLA disparity on the risk of overall mortality in patients with grade II–IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2021, 56, 2990-2996.	1.3	2
118	Idiopathic CD4 Lymphocytopenia Due to Loss of Heterozygosity of the Mutant CD2 Gene. Blood, 2010, 116, 2774-2774.	0.6	2
119	Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplantation, 2022, 57, 243-251.	1.3	2
120	Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation. Bone Marrow Transplantation, 2022, , .	1.3	2
121	Nuclear Ceramide Is Associated with Ataxia Telangiectasia Mutated Activation in the Neocarzinostatin-Induced Apoptosis of Lymphoblastoid Cells. Molecular Pharmacology, 2022, 101, 322-333.	1.0	2
122	Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch. Bone Marrow Transplantation, 2022, 57, 1171-1179.	1.3	2
123	Successful treatment of severe acute gastrointestinal graft-versus-host disease complicated by cytomegalovirus gastroenteritis with intra-arterial steroid infusion. Annals of Hematology, 2016, 95, 1373-1375.	0.8	1
124	Significance of an intensified myeloablative conditioning regimen for myeloid malignancy and acute lymphoblastic leukemia. Journal of Hematopoietic Cell Transplantation, 2017, 7, 1-8.	0.1	1
125	High-dose cytarabine chemotherapy (≥4 g/m2/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission. Leukemia and Lymphoma, 2020, 61, 3128-3136.	0.6	1
126	A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. British Journal of Haematology, 2021, 195, 217-229.	1.2	1

#	Article	IF	CITATIONS
127	Patient-Reported Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Types and Severity of Chronic Gvhd. Blood, 2016, 128, 1240-1240.	0.6	1
128	Changes in the health-related quality of life and social reintegration status after lung transplantation following hematopoietic stem cell transplantation. Supportive Care in Cancer, 2022, 30, 1831-1839.	1.0	1
129	Impact of Serum Ferritin Levels on the Incidence of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2010, 116, 1248-1248.	0.6	1
130	Risk Factors and Predictive Scoring System for Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 250-250.	0.6	1
131	The characteristics of changes in skeletal muscle cross-sectional area after allogeneic hematopoietic stem cell transplantation. Journal of Hematopoietic Cell Transplantation, 2019, 8, 70-77.	0.1	1
132	Establishment of a Predictive Model of GvHD-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm. Blood, 2019, 134, 3337-3337.	0.6	1
133	The Impact of Anti-Microbial Drug-Drug Interactions on Acute Kidney Injury after Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 29-30.	0.6	1
134	Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation. Bone Marrow Transplantation, 2022, 57, 407-415.	1.3	1
135	Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia. International Journal of Hematology, 2022, 116, 453-458.	0.7	1
136	Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA. Annals of Hematology, 2022, 101, 1129-1132.	0.8	1
137	Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation. Bone Marrow Transplantation, 2022, 57, 1198-1200.	1.3	1
138	Intramuscular Adipose Tissue Content Predicts Patient Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 602.e1-602.e7.	0.6	1
139	Health-related QOL challenges and coping ability of patients after treatment for acute leukemia: qualitative analysis. Journal of Illusion, 2022, 11, 177-186.	0.0	1
140	Familial Mediterranean fever mutations in a patient with recurrent episodes of acute respiratory distress syndrome. Clinical Immunology, 2013, 147, 58-60.	1.4	0
141	Response to the Comment by Cirasino L and Semeraro S: "Need to direct immune thrombocytopenia therapy towards shared goals―Direct and indirect comparisons to determine the first choice for newly diagnosed primary immune thrombocytopenia in adults. Haematologica, 2018, 103, e269-e269.	1.7	Ο
142	EBVâ€associated lymphoproliferative disorder in a patient with Xâ€linked severe combined immunodeficiency with multiple reversions of an <i>IL2RG</i> mutation in T cells. EJHaem, 2020, 1, 581-584.	0.4	0
143	Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. British Journal of Haematology, 2021, 192, e7-e11.	1.2	0
144	PD-1/PD-1-Ligand Interaction Contributes to Immunosuppressive Microenvironment of Hodgkin Lymphoma Blood, 2007, 110, 379-379.	0.6	0

#	Article	IF	CITATIONS
145	Reactivation of Human Herpes Virus 6 (HHV6) during Hematopoietic Stem Cell Transplantation: Risk Factor Analysis of HHV6 Encephalitis and Survival Blood, 2008, 112, 2224-2224.	0.6	0
146	Clinical Significance of Serum Hepcidin-25 Levels on Early Treatment-Related Complications after Hematopoietic Stem Cell Transplantation. Blood, 2008, 112, 1160-1160.	0.6	0
147	Clinical Significance of Severity and Subcategory of Chronic GVHD Evaluated by NIH Consensus Criteria Blood, 2009, 114, 2218-2218.	0.6	Ο
148	Serum Neutrophil Extracellular Traps (NETs) Are a Potential Predictive Marker for Thrombotic Microangiopathy (TMA) After Allogeneic Stem Cell Transplantation. Blood, 2012, 120, 1919-1919.	0.6	0
149	Outcome and Prognostic Index for Reduced-Intensity Allogeneic Stem Cell Transplantation (RIST) for Elderly Patients with De Novo Acute Myeloid Leukemia (AML): A Study From the AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Blood, 2012, 120, 1918-1918.	0.6	0
150	Long-term remission in patients with plasma cell myeloma after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation:. Journal of Hematopoietic Cell Transplantation, 2013, 2, 25-31.	0.1	0
151	Pleurisy as a novel clinical manifestation associated with human herpesvirus 6 after unrelated cord blood transplantation. Journal of Hematopoietic Cell Transplantation, 2014, 3, 59-63.	0.1	0
152	Ceramide Regulates MRN Complexâ€ATMâ€Dependent Apoptotic Pathway in Human Lymphoblastoids. FASEB Journal, 2015, 29, 568.4.	0.2	0
153	Adolescents and Young Adults with Acute Myeloid Leukemia Are Associated with Higher Treatment-Related Mortality and Inferior Overall Survival after Allogeneic Hematopoietic Cell Transplantation Compared with Children. Blood, 2016, 128, 4702-4702.	0.6	0
154	Clinical Outcomes of Patients with Primary Myelofibrosis in Japan: A Nationwide Survey over a 17-Year Study Period. Blood, 2016, 128, 3126-3126.	0.6	0
155	Central Nervous System Invasion in Multiple Myeloma: A Nationwide Survey of 75 Patients in Japan. Blood, 2016, 128, 4493-4493.	0.6	0
156	A single-center retrospective analysis of extramedullary relapse after allogeneic stem cell transplantation for myeloid neoplasms. Journal of Hematopoietic Cell Transplantation, 2018, 7, 138-144.	0.1	0
157	Clinical Analysis of Immunodeficiency-Associated Lymphoproliferative Disorders in a Single Institution. Blood, 2018, 132, 5398-5398.	0.6	0
158	Risk Factors and the Therapeutic Efficacy for Thrombotic Microangiopathy in Patients after Allogeneic Hematopoietic Stem Cell Transplantation - Results of the Multicenter Retrospective Cohort Study. Blood, 2019, 134, 4554-4554.	0.6	0
159	Impact of HLA Class I Allele Mismatch on Viral Infection within 100 Days after Cord Blood Transplantation. Blood, 2019, 134, 3267-3267.	0.6	0
160	Comparing Single Cord Blood Transplantation and Matched Related Donor Transplantation in Non-Remission Acute Myeloid Leukemia. Blood, 2021, 138, 1790-1790.	0.6	0
161	Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies. Blood, 2021, 138, 2927-2927.	0.6	0
162	Aplastic Anemia Treated with Eltrombopag during Pregnancy. Case Reports in Obstetrics and Gynecology, 2022, 2022, 1-4.	0.2	0